Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06625593 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 1
Development phase
168
Enrollment target
20
Study locations

NCT06625593 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 168 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06625593, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 1
Development phase
168 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (Monotherapy Dose Escalation, and Safety Expansion; Combination Dose Confirmation and Safety Expansion) and Phase 1b (Dose Expansion).

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG BG-C137
  • DRUG Anticancer Agents

Study Locations (20)

New South Wales

  • Blacktown Cancer and Haematology Centre - Blacktown
  • Liverpool Hospital - Liverpool

Victoria

  • Monash Health - Clayton
  • Cabrini Hospital Malvern - Malvern East

Henan

  • The First Affiliated Hospital of Henan University of Science and Technology - Luoyang
  • Henan Cancer Hospital - Zhengzhou

California

  • Usc Norris Comprehensive Cancer Center (Nccc) - Los Angeles

Connecticut

  • Yale Cancer Center - New Haven

Minnesota

  • Mayo Clinic Rochester - Rochester

Texas

  • Md Anderson Cancer Center - Houston

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2024-12-09
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

BeOne Medicines

29 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06625593

The ClinicalTrials.gov registry entry for NCT06625593 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (12% lower). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which BG-C137 is the first listed.

NCT06625593 reports 20 study locations spanning 17 distinct geographic areas - top geographies include New South Wales, Victoria, Henan.

Frequently Asked Questions

What is clinical trial NCT06625593 about?

NCT06625593 is a clinical study titled "A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (M...

What is the current status of trial NCT06625593?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2024-12-09. Estimated completion is 2026-12-31.

What conditions does trial NCT06625593 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06625593?

The interventions under investigation include: BG-C137 (DRUG), Anticancer Agents (DRUG).

Who is sponsoring clinical trial NCT06625593?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06625593 being conducted?

This trial has 20 study locations across California, Connecticut, Minnesota, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.